<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00850746</url>
  </required_header>
  <id_info>
    <org_study_id>443-CL-048</org_study_id>
    <nct_id>NCT00850746</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Adults</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo- and Active- Controlled, Crossover Study to Evaluate the Effect of Repeat Oral Doses of YM443 on Cardiac Repolarization in Healthy Male and Female Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether YM443 causes any changes in the electrocardiogram of healthy
      adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each subject participates in all four treatment periods separated by washout periods.

      In order to maintain the blind between arms, all subjects will receive the same number of
      tablets per day in each period of either active drug or placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in the QTcF (Fridericia's correction) between each active treatment and placebo</measure>
    <time_frame>Following four days of dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mean change of the QTcI (Individual correction) and QTcB (Bazett's correction) between each active treatment and placebo.</measure>
    <time_frame>Following four days of dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The pharmacokinetics of YM443 in these subjects</measure>
    <time_frame>Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The safety and tolerability of YM443</measure>
    <time_frame>Following four days of dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>A. Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B. Ym443 Lower Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C. YM443 Higher Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D. Moxiflocxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YM443</intervention_name>
    <description>Oral</description>
    <arm_group_label>B. Ym443 Lower Dose</arm_group_label>
    <arm_group_label>C. YM443 Higher Dose</arm_group_label>
    <other_name>Z-338</other_name>
    <other_name>acotiamide hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>A. Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>Oral</description>
    <arm_group_label>D. Moxiflocxacin</arm_group_label>
    <other_name>Avelox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Male or non pregnant, non lactating female

          -  Weighing at least 45 kg

          -  Body Mass Index (BMI) between 18 and 32 kg/m2

        Exclusion Criteria:

          -  The subject has evidence of any cardiac conduction abnormalities

          -  The subject has a previous history of any medical or psychiatric condition that would
             preclude participation in the study

          -  The subject has participated in another clinical trial in the last 30 days

          -  The subject anticipates an inability to abstain from alcohol, or caffeine use, or from
             grapefruit and grapefruit juice from 48 hours prior to the administration of the first
             dose of YM443 on Day 1 of Period 1 and throughout the duration of the study

          -  The subject has used tobacco-containing products and nicotine or nicotine-containing
             products within six months prior to Screening

          -  The subject consumes more than 5 units of alcoholic beverages (one unit is 12 ounces
             of beer, 4 ounces of wine or 1 ounce of spirits) per week or has a history of
             substance abuse, drug addiction, or alcoholism within 2 years prior to Screening

          -  The subject has donated any whole blood or cellular blood component or has undergone
             significant loss of blood or has received transfusion of any blood or blood products
             within 56 days of Day -1 of Period 1 or has donated plasma within 7 days of Day -1 of
             Period 1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=1008</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2009</study_first_submitted>
  <study_first_submitted_qc>February 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2009</study_first_posted>
  <last_update_submitted>March 21, 2014</last_update_submitted>
  <last_update_submitted_qc>March 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>QT interval</keyword>
  <keyword>Cardiac Repolarization</keyword>
  <keyword>Cardiac Conduction</keyword>
  <keyword>Healthy Subjects</keyword>
  <keyword>YM443 (Z-338, acotiamide hydrochloride)</keyword>
  <keyword>Evaluation of QT Interval</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

